Finally, when the long-term antitumor effects of OBP-702 were evaluated using the same PAN02 bilateral subcutaneous tumor model (Fig. 6A), intratumoral injection of OBP-702 significantly suppressed the tumor growth on both treated and untreated sides compared with Ad-p53 and OBP-301 28 days after treatment initiation (Fig. 6B, Fig. S7). This evidence concerns the gene TP53 and neoplasm.